| Literature DB >> 28674509 |
David G Juncos1, Glenn A Heinrichs1, Philip Towle2, Kiera Duffy3, Sebastian M Grand4, Matthew C Morgan5, Jonathan D Smith6, Evan Kalkus7.
Abstract
This study investigated the use of Acceptance and Commitment Therapy (ACT) as a treatment for music performance anxiety (MPA) in an uncontrolled pilot design. ACT is a newer, "third-wave" therapy that differs from previous MPA treatments, because its goal is not to reduce symptoms of MPA. Rather, ACT aims to enhance psychological flexibility in the presence of unwanted symptoms through the promotion of six core processes collectively known as the ACT "Hexaflex." A small group of student vocalists (N = 7) from an elite choral college were recruited using objective criteria for evaluating MPA. Participants received 12 ACT sessions, and their baseline functioning served as a pre-treatment control. Treatment consisted of an orientation to ACT, identifying experientially avoidant behaviors, facilitation of Hexaflex processes, group performances in which valued behaviors were practiced in front of one another, meditations, homework, and completion of self-report measures before, during, and after treatment (at a 1- and 3-month follow-up). Improvements were observed in participants' cognitive defusion, acceptance of MPA symptoms, and psychological flexibility at post-treatment and follow-ups. Students also appeared to improve their performance quality and reduce their shame over having MPA. These results add to existing research suggesting ACT is a promising intervention for MPA, while also highlighting how vocal students may be less impaired by physical MPA symptoms.Entities:
Keywords: acceptance and commitment therapy; hexaflex; music performance anxiety; pilot study; psychological flexibility; vocalists
Year: 2017 PMID: 28674509 PMCID: PMC5475388 DOI: 10.3389/fpsyg.2017.00986
Source DB: PubMed Journal: Front Psychol ISSN: 1664-1078
Figure 1The ACT hexaflex.
Descriptive data and mean scores on ACT-based measures, as well as results of paired t-tests comparing pre-treatment means (Baseline 1 & 2) to means at post-treatment, 1-month follow-up, and 3-month follow-up.
| B1 (Pre-tx) | |||||
| B2 (Pre-tx) | |||||
| S12 (Post-tx) | |||||
| FU1 | |||||
| FU2 | |||||
Normative means and standard deviations for the
BAFT,
PHLMS,
AAQ-II, and
VLQ were taken from non-clinical samples of undergraduates used in each measures' validation study;
Statistically significant result at p < 0.05 level compared to B1 mean;
Statistically significant result at p < 0.05 level compared to B2 mean; B, Baseline; S, Session; FU, Follow-Up.
Figure 2Mean performance quality ratings for students' pre- and post-treatment video-recordings using three independent raters' average scores on the MPQ. Time 1 = Pre-treatment; Time 2 = Post-treatment.
Figure 3Mean performance quality ratings for students' pre- and post-treatment video-recordings using three independent raters' overall scores on the MPQ. Time 1 = Pre-treatment; Time 2 = Post-treatment.
Descriptive data and mean scores on an MPA-based and other anxiety measure, as well as results of paired t-tests comparing pre-treatment means (Baseline 1 & 2) to means at post-treatment, 1-month follow-up, and 3-month follow-up.
| Cutoff = 105 | ||
| B1 (Pre-tx) | ||
| B2 (Pre-tx) | ||
| S12 (Post-tx) | ||
| FU1 | ||
| FU2 | ||
KMPAI normative data was from a group of professional orchestral musicians in Australia under age 30;
Recommended cutoff score for determining clinically significant MPA;
ACQ normative data was from non-clinical samples of undergraduates;
Statistically significant result at p < 0.05 level compared to B1 mean;
Statistically significant result at p < 0.05 level compared to B2 mean;
Below recommended cutoff score.
Figure 4BAFT scores from the baseline period to post-treatment, 1- and 3-month follow-up points, including the non-clinical mean (50.10) and standard deviation bars (SD = 16.88; Herzberg et al., 2012).
Figure 5AAQ-II scores from the baseline period to post-treatment, 1- and 3-month follow-up points, including the non-clinical mean (17.34) and standard deviation bars (SD = 4.37; Bond et al., 2011).
Figure 6PHLMS Acceptance subscale scores from the baseline period to post-treatment, 1- and 3-month follow-up points, including the non-clinical mean (30.19) and standard deviation bars (SD = 5.84; Cardaciotto et al., 2008).
Figure 7KMPAI scores from the baseline period to post-treatment, 1- and 3-month follow-up points, including the mean for musicians under age 30 (93.5), standard deviation bars (SD = 39.1; Kenny et al., 2012), and the recommended clinical cutoff score (105; Ackermann et al., 2014).
Figure 8ESS scores from six peer performances with piano accompaniment, including the non-clinical mean (3.9) and standard deviation bars (SD = 0.73; Turner, 2014).